129449-09-8

Basic information

• Product Name: Amino-PEG10-alcohol
• Synonyms: Amino-PEG10-alcohol;H2N-PEG10-OH;3,6,9,12,15,18,21,24,27-Nonaoxanonacosan-1-ol, 29-amino-
• CAS NO: 129449-09-8
• Molecular Formula: C₂₀H₄₃NO₁₀
• Molecular Weight: 457.55612
• Mol File: 129449-09-8.mol

Chemical Properties

• Boiling Point: 533.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.096±0.06 g/cm3(Predicted)
• PKA: 14.36±0.10(Predicted)
• CAS DataBase Reference: Amino-PEG10-alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: Amino-PEG10-alcohol(129449-09-8)
• EPA Substance Registry System: Amino-PEG10-alcohol(129449-09-8)

Safety Data

• Hazardous Substances Data: 129449-09-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Amino-PEG10-alcohol is used as a solubilizing agent for enhancing the water solubility of hydrophobic drugs, thereby improving their bioavailability and pharmacokinetic properties.
Used in Drug Delivery Systems:
Amino-PEG10-alcohol is used as a component in the design and synthesis of drug delivery systems, such as nanoparticles, liposomes, and hydrogels, due to its biocompatible and hydrophilic nature. It can also be used for targeting and controlled release of therapeutic agents.
Used in Chemical Synthesis:
Amino-PEG10-alcohol is used as a building block or intermediate in the synthesis of various PEGylated compounds, including PEGylated proteins, peptides, and small molecules, for a range of applications in biotechnology and pharmaceuticals.
Used in Diagnostics:
Amino-PEG10-alcohol is used as a modifier to enhance the stability and solubility of diagnostic agents, such as contrast agents for imaging techniques like magnetic resonance imaging (MRI) and computed tomography (CT).
Used in Material Science:
Amino-PEG10-alcohol is used as a component in the development of biocompatible and hydrophilic materials, such as coatings, surfaces, and scaffolds for tissue engineering and regenerative medicine applications.
Used in Cosmetics:
Amino-PEG10-alcohol is used as an ingredient in the formulation of cosmetics and personal care products, where it serves as a humectant, emollient, and solubilizing agent for various active ingredients.

Upstream product

• 125274-14-8 2-{2-[2-(2-{2-[2-(2-{2-[2-(2-trityloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethanol 
• 745048-16-2 19,19,19-triphenyl-3,6,9,12,15,18-hexaoxanonadec-1-ylmethanesulfonate 
• 127999-16-0 19-(triphenylmethyl)-1,4,7,10,13,16,19-heptaoxanonadecanol 
• 877239-08-2 1-azide-31,31,31-triphenyl-3,6,9,12,15,18,21,24,27,30-decaoxahentriacontanol 
• 352439-38-4 1-azido-17-(methylsulfonyl)oxy-3,6,9,12,15-pentaoxaheptadecane 
• 352439-34-0 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl methanesulfonate 
• 125274-16-0 1,1,1-triphenyl-2,5,8,11-tetraoxatridecan-13-ol 
• 86770-69-6 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 2615-15-8 pentaethylene glycol 
• 112-60-7 Tetraethylene glycol 
• 877239-09-3 1-azido-29-hydroxy-3,6,9,12,15,18,21,24,27-nonaoxanonacosane 

Downstream Products

• 1426687-12-8 1-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-2-oxo-6,9,12,15,18,21,24,27,30-nonaoxa-3-azadotriacontan-32-yl methanesulfonate 
• 1426686-71-6 N-(29-(((4S)-6-(4-chlorophenyl)-4-(2-(ethylamino)-2-oxoethyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-8-yl)oxy)-3,6,9,12,15,18,21,24,27-nonaoxanonacosyl)-2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)acetamide 
• 1426687-13-9 2-((4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-N-(29-hydroxy-3,6,9,12,15,18,21,24,27-nonaoxanonacosyl)acetamide 

Relevant articles and documents

PROTAC compound for targeted degradation of IDO1, and preparation method and application thereof

The invention provides a PROTAC compound represented by formula I and used for targeted degradation of IDO1, and a pharmaceutically acceptable salt, a hydrate or a solvate thereof. In the formula I, Xrepresents -CH2 or -C = O, Y represents -CH2 or -C= O, and n is a natural number from 2 to 9. The PROTAC compound for targeted degradation of the IDO1 has efficient activity of targeted degradation of the IDO1 protein.

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

GALACTOSE DERIVATIVE, DRUG CARRIER AND MEDICINAL COMPOSITION

The object of the invention is to provide a novel and useful galactose derivative constituting a drug carrier by which a medicine can be efficiently transferred into the liver, a drug carrier comprising the derivative, and a pharmaceutical composition comprising the carrier and a medicine. The present invention relates to a galactose derivative made up of galactose, a suitable spacer and a certain lipid, a drug carrier comprising the derivative and a cationic lipid, and a pharmaceutical composition comprising the carrier and a medicine (preferably a double strand RNA, a double strand DNA, an oligo nucleic acid) .

Synthesis of a series of oligo(ethylene glycol)-terminated alkanethiol amides designed to address structure and stability of biosensing interfaces

A strategy for the synthesis of a series of closely related oligo(ethylene glycol)-terminated alkanethiol amides (principally HS(CH2)mCONH(CH2CH2O) nH; m = 2, 5, 11, 15, n = 1, 2, 4, 6, 8, 10, 12) and analogous esters has been developed. These compounds were made to study the structure and stability of self-assembled monolayers (SAMs) on gold in the prospect of designing new biosensing interfaces. For this purpose, monodisperse heterofunctional oligo(ethylene glycols) with up to 12 units were prepared. Selective monoacylation of the symmetrical tetra- and hexa(ethylene glycol) diols as their mesylates with the use of silver(I) oxide was performed. The synthetic approach was based on carbodiimide couplings of various oligo(ethylene glycol) derivatives to ω-(acetylthio) carboxylic acids via a terminal amino or hydroxyl function. SAM structures on gold were studied with respect to thickness, wettability (water contact angles ～30°), and conformation. A good fit was obtained for the relation between monolayer thickness (d) and the number of units in the oligo(ethylene glycol) chain (n): d = 2.8n + 21.8 (A). Interestingly, the corresponding infrared spectroscopy analysis showed a dramatic change in conformation of the oligomeric chains from all-trans (n = 4) to helical (n ≥ 6) conformation. A crystalline helical structure was observed in the SAMs for n > 6.